[Cardiovascular prevention of high risk patients by hypolipidemic treatment].
Afssaps guidelines 2005 for the treatment of dyslipidemic patients provide a valuable tool for optimal treatment in clear cut situations. However, for patients with intermediate cardiovascular risk or when it might be necessary to intensify hypolipidemic treatment, additional risk markers can be contributive for risk estimation (CRP, intima-media thickness) and it is usefull to take into account the physiopathology of dyslipidemia and subgroup analysis of clinical trials. An efficient cardiovascular prevention implies a screening of high cardiovascular risk subjects, an optimal treatment and conversely not to over treat low risk subjects. In France, convergent studies show under treatment of high risk subjects and over treatment of low risk dyslipidemic subjects.
Moulin
Philippe
P
Federation d'endocrinologie et des maladies de la nutrition, hôpital cardiovasculaire Louis Pradel, 69677 Lyon Bron. philippe.moulin@chu-lyon.fr
Sérusclat
André
A
Bernard
Sophie
S
D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004032:Diet; D050171:Dyslipidemias / Q000628:therapy*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D012307:Risk Factors
D000960:Hypolipidemic Agents